

Docket No.: NIH147.001D1

October 27, 2005

App. No.: 10/057,113

Page 1 of 2

Customer Number 45311

**TERMINAL DISCLAIMER UNDER 37 CFR § 1.321**

Applicant : Szkudlinski et al.  
App. No : 10/057,113  
Filed : January 25, 2002  
For : GLYCOPROTEIN HORMONE  
SUPERAGONISTS  
Examiner : Spector, Lorraine  
Art Unit : 1647

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

***Right of Assignee and Ownership***

In accordance with 37 C.F.R. § 3.73(b), Assignee represents that it is the owner of a 100 percent interest in the above-identified application and co-owned, Patent No. 6,361,992, all by virtue of an assignment recorded at Reel No. 9789, Frame No. 0086 by the Assignment Branch of the Patent and Trademark Office. The Assignee represents that, to the best of Assignee's knowledge and belief, title is in the Assignee seeking to take action.

***Disclaimer by Assignee***

Assignee, The Government of the United States of America as represented by the Secretary, Department of Health and Human Services ("Assignee"), hereby disclaims, except as provided below, the terminal part of any patent granted on the above-referenced application which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,361,992, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the above-identified application and U.S. Patent No. 6,361,992 are co-owned. This agreement extends to any patent granted on the above-referenced application and shall be binding on its successors or assigns.

Docket No.: NIH147.001D1  
App. No.: 10/057,113

October 27, 2005  
Page 2 of 2

Customer Number 45311

Assignee does not disclaim any terminal part of any patent granted on the above-referenced application prior to the earlier of the expiration date of the full statutory term of U.S. Patent No. 6,361,992, and that of any patent issuing on the above-identified application in the event that either one later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term, except for the separation of legal title stated above.

This Terminal Disclaimer is accompanied by the \$130 fee set forth in 37 C.F.R. § 1.20(d).  
Done on this \_\_\_\_\_ day of October, 2005, at Rockville, Maryland.

UNITED STATES DEPARTMENT OF HEALTH  
AND HUMAN SERVICES

By: Marlene Astor

Printed Name: Marlene Astor

Registration No.: 46,005

for:  
Office of Technology Transfer  
National Institutes of Health  
6011 Executive Boulevard, Suite 325  
Rockville, MD 20852  
Telephone (301) 496-7056  
Facsimile (301) 402-0220